Phaseline

Companies › NGGT (Suzhou) Biotechnology

NGGT (Suzhou) Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology, Metabolic and endocrine; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NGGT002
adeno-associated viral vector with human phenylalanine hydroxylase gene
PAHPhase 1PhenylketonuriasAug 2027
NGGT001
AAV-mediated CYP4V2 gene delivery via subretinal injection
CYP4V2Phase 1Bietti Crystalline Corneoretinal DystrophySep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06687733NGGT002Phase 1PhenylketonuriasMetabolic and endocrineAug 2027
NCT06706427NGGT001Phase 1Bietti Crystalline Corneoretinal DystrophyOphthalmologySep 2029

Targets

CYP4V2 (1) PAH (1)

Companies with the same targets

BioMarin Pharmaceutical Shanghai Vitalgen BioPharma PTC Therapeutics Chongqing Peg-Bio Biopharm NGGT Agios Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.